A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer - The UK NCRN Pomi-T study

Prostate Cancer and Prostatic Diseases

Volumn 17, Issue 2, 2014, Pages 180-186

  Thomas, R ^a,b,c   Williams, M ^a   Sharma, H ^a   Chaudry, A ^b   Bellamy, P ^c  

^a BEDFORD HOSPITAL   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c CRANFIELD UNIVERSITY   (United Kingdom)

Author keywords

active surveillance; nutrition; watchful waiting

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HERBACEOUS AGENT; POLYPHENOL; PROSTATE SPECIFIC ANTIGEN; SUGAR; TURMERIC; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; TEA;

ADVERSE OUTCOME; AGE; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; BROCCOLI; CANCER LOCALIZATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FOOD COMPOSITION; GLEASON SCORE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; POMEGRANATE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TEA; THERAPY EFFECT; UNITED KINGDOM; WATCHFUL WAITING; BLOOD; BRASSICA; CURCUMA; DIET THERAPY; DISEASE COURSE; LYTHRACEAE; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRASSICA; CURCUMA; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; POLYPHENOLS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PUNICACEAE; TEA;

EID: 84901197775     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2014.6     Document Type: Article

References (50)

1. Hu F, Wang YB, Liang J, Yi B, Zhang W, Liang J et al. Carotenoids and breast cancer risk: A meta-Analysis and meta-regression. Breast Cancer Res Treat 2012; 131: 239-253
2. Wu AH, Yu MC. Tea, hormone-related cancers and endogenous hormone levels. Mol Nutr Food Res 2006; 50: 160-169
3. Banim PJ, Luben R, McTaggart A, Welch A, Wareham N, Khaw KT et al. Dietary antioxidants and the aetiology of pancreatic cancer. Gut 2013; 62: 1489-1496
4. Tung K, Wilkens LR, Wu AH, McDuffie K, Hankin JH, Nomura AM et al. Association of dietary vitamin A, carotenoids and other antioxidants with the risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 669-676
5. Heinen MM, Hughes MC, Ibiebele TI, Marks GC. Intake of antioxidant nutrients and the risk of skin cancer. EJC 2007; 43: 2707-2716
6. Giovannucci E, Rimm EB, Liu Y, Meir J, Stampfer MJ, Walter C et al. A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 2002; 94: 391-398
7. Joseph MA, Moysich KB, Freudenheim JL, Shields PG, Bowman ED, Zhang Y et al. Cruciferous vegetables, genetic polymorphisms and prostate cancer risk. Nutr Cancer 2004; 50: 206-213
8. Steward A, Gescher AJ. Curcumin in cancer management: Recent results of analogue design and clinical studies and desirable future research. Mol Nutr Food Res 2008; 52: 1005-2009
9. Sun CL, Yuan JM, Koh WP, Lee HP, Yu MC. Green tea and black tea consumption and colorectal cancer risk: The Singapore Chinese Health Study. Carcinogenesis 2007; 28: 2143-2148
10. Pierce JP, Natarajan L, Caan BJ, Parker BA, Greenberg ER, Flatt SW et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: The Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 2007; 298: 289-298
11. Buck K, Vrieling A, Zaineddin AK, Becker S, Hü sing A, Kaaks R et al. Serum enterolactone and prognosis of postmenopausal breast cancer. J Clin Oncol 2011; 29: 3730-3738
12. Boyapati SM, Shu XO, Ruan ZX, Dai Q, Cai Q, Gao YT et al. Soy food intake and breast cancer survival: A follow up of the Shanghai Breast Cancer Study. Breast Cancer Res Treat 2005; 92: 11-17
13. Ogunleye AA, Xue F, Michels KB. Green tea and breast cancer risk of recurrence: A meta-Analysis. Breast Cancer Res Treat 2010; 119: 477
14. Ornish D, Magbanua MJM, Weidner G, Weinberg V, Kemp C, Green C et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 2005; 174: 1065-1070
15. Thomas R, Oakes R, Gordon J, Russell S, Blades M, Williams M. A randomised, double-blind phase II study of lifestyle counselling and salicylate compounds in patients with progressive prostate cancer. Nutr Food Sci 2009; 39: 295-305
16. Meyer F, Galan P, Douville P, Bairati I, Kegle P, Bertrais S et al. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer 2005; 116: 182-186
17. Schrö Der FH, Roobol MJ, Boeve-ER, De Mutsert R, Zuijdgeest-van Leeuwen SD, Kersten I et al. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: Effectiveness of a dietary supplement. Eur Urol 2005; 48: 922-930
18. Brasky TM, Kristal AR, Navarro SL, Lampe JW, Peters U, Patterson RE et al. Specialty supplements and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort. Nutr Cancer 2011; 63: 573-582
19. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A et al. Risk factors for lung cancer and for intervention effects in CARET, the beta-carotene in retinol efficacy trial. J Natl Cancer Inst 1996; 88: 1550-1559
20. Heinonen O, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM et al. Prostate cancer and supplementation with alpha-Tocopherol and betacarotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 1998; 90: 440-446
21. Figueiredo JC, Grau MV, Haile RW, Sandler RS, Summers RS, Bresalier RS et al. Folic acid and risk of prostate cancer: Results from a randomized clinical trial. J Natl Cancer Inst 2009; 101: 432-435
22. Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ et al. Vitamin E and the risk of prostate cancer: The selenium and vitamin E cancer prevention Trial (SELECT). JAMA 2011; 306: 1549-1556
23. Leitzmann MF, Stampfer MJ, Wu K, Colditz GA, Willet WC, Giovannucci EL. Zinc supplementation and the risks of prostate cancer. J Natl Cancer Inst 2003; 95: 1004-1007
24. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H et al. Saw Palmetto for benign prostatic hyperplasia. N Engl J Med 2006; 354: 557-566
25. Barber NJ, Zhang X, Zhu G, Pramanik R, Barber JA, Martin FL et al. Lycopene inhibits DNA synthesis in primary prostate epithelial cells in vitro and its administration is associated with a reduced prostate-specific antigen velocity in a phase II clinical study. Prostate Cancer Prostatic Dis 2006; 9: 407-413
26. Clark PE, Hall MC, Borden LS, Clark PE, Miller AA, Hu JJ et al. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology 2006; 67: 1257-1261
27. Wang L, Alcon A, Yuan H, Ho J, Li QJ, Martins-Green M. Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells. Integr Biol (Camb) 2011; 3: 742-754
28. Pantuck AJ, Leppert JT, Zomorodian N, Seeram N, Seiler D, Liker H et al. Phase II study of pomegranate juice for men with rising PSA following surgery or radiation for prostate cancer. J Urol 2005; 173: 225-226
29. Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold HR et al. A randomised phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis 2013; 16: 50-55.
30. Rettig MB, Heber D, An J, Seeram NP, Rao JY, Liu H et al. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factorkappaB- dependent mechanism. Mol Cancer Ther 2008; 7: 2662-2671
31. Lansky EP, Harrison G, Froom P, Jiang WG. Pomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel. Invest New Drugs 2005; 23: 121-122
32. Malik A, Mukhtar H. Prostate cancer prevention through pomegranate fruit. Cell Cycle 2006; 5: 371-373
33. Khan N, Hadi N, Afaq F, Syed DN, Kweon MH, Mukhtar H. Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice. Carcinogenesis 2007; 28: 163-173
34. Choi C, Kim JK, Choi SH, Jung HS, Kim HJ, Cho SY et al. Identification of steroid hormones in pomegranate (Punica granatum) using HPLC and GC-mass spectrometry. Food Chemistry 2006; 96: 562-571
35. Liao S, Kao YH, Hiipalla RA. Green tea: Biochemical and biological basis for health benefits. Vitam Horm 2001; 62: 1-94
36. Porrini M, Riso P. Factors influencing the bioavailability of antioxidants in foods: A critical appraisal. Nutr Metab Cardiovas 2008; 80: 353-361
37. Liao J, Yang GY, Park ES, Meng X, Sun Y, Jia D et al. Inhibition of lung carcinogenesis and effects on angiogenesis and apoptosis in mice given green tea. Nutr Cancer 2004; 48: 44-53
38. Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 2002; 42: 25-54
39. Traka M, Gasper AV, Melchini A, Bacon JR, Needs PW, Frost V et al. The dietary isothiocyanate sulforaphane modulates gene expression and alternative gene splicing in a PTEN null preclinical murine model of prostate cancer. Mol Cancer 2010; 9: Doi:10.1186/1476-4598-9-189
40. Gasper AV, Al-Janobi A, Smith JA, Bacon RJ, Fortun P, Atherton C et al. Glutathione S-Transferase M1 polymorphism and metabolism of sulforaphane from standard and high-glucosinolate broccoli. Am J Clin Nutr 2005; 82: 1283-1291
41. Shah BH, Nawaz Z, Pertani SA, Roomi A, Mahmood H, Saeed SA et al. Inhibitory effect of curcumin, a food spice from turmeric, on platelet-Activating factorand arachidonic acidmediated platelet aggregation through inhibition of thromboxane formation and Ca2- signaling. Biochem Pharmacol 1999; 58: 1167-1172
42. Zhang HN, Yu CX, Chen WW, Jiang AL, Kong F, Deng DJ et al. Curcumin down regulates gene NKX3.1 in prostate cancer cell lines (LNcaP). Acta Pharmacol Sin 2007; 28: 423-430
43. Iqbal M, Sharma SD, Okazaki Y, Fujisawa M, Okada S. Dietary supplementation of curcurmin enhances antioxidant phase II metabolosing enzymes in mice. Pharmacol Toxicol 2003; 92: 33-38
44. Somasundaram S, Edmund NA, Moore DT, Small GW, Shhi YY, Orlowski RZ. Curcumin inhibits chemotherapy-induced apoptosis in models of cancer. Cancer Res 2002; 62: 3868-3875
45. Dorai T, Gehani N, Buttyan R, Katz AE. Therapeutic potential of curcumin in human prostate cancer. Curcumin inhibits tyrosine kinase activity of the Epidermal growth factor receptor. Mol Urol 2000; 4: 1-6
46. Handler N, Jaeger W, Puschacher H, Leisser K, Erker T. Synthesis of noval curcumin analogues and their evaluation as selective cyclooxygenase-1 inhibitors. Chem Pharm Bull 2007; 55: 64-71
47. Bauer CM, Johnson EK, Beebe-Dimmer JL, Cooney KA. Prevalence and correlates of vitamin and supplement usage amongst men with prostate cancer. Integr Cancer Ther 2012; 11: 83-89
48. Freedland SJ, Carducci M, Kroeger N, Partin A, Rao JY, Jin Y et al. A double blind randomised neoadjuvant study of the tissue effects of Pomx pills in men with prostate cancer before radical prostatectomy. Cancer Prev Res (Phila) 2013; 6: 1120-1127
49. Parada J, Aguilera JM. Food combinations and microstructure affects the bioavailability of several nutrients. J Food Sci 2007; 72: 21-23
50. Kakarla M, Brenner DE, Khorkya H, Cheng C, Tazi K, Ginestier C et al. Targeting breast stem cells with the preventive compounds curcumin and piperine. Breast Cancer Res Treat 2010; 122: 777-785